Asset Details
Do you wish to reserve the book?
How to deal with a temporary suspension and restarting your trial: our experiences and lessons learnt
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
How to deal with a temporary suspension and restarting your trial: our experiences and lessons learnt
Do you wish to request the book?
How to deal with a temporary suspension and restarting your trial: our experiences and lessons learnt
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
How to deal with a temporary suspension and restarting your trial: our experiences and lessons learnt
2020
Overview
Whilst the issues around early termination of randomised controlled trials (RCTs) are well documented in the literature, trials can also be temporarily suspended with the real prospect that they may subsequently restart. There is little guidance in the literature as to how to manage such a temporary suspension. In this paper, we describe the temporary suspension of a trial within our clinical trials unit because of concerns over the safety of transvaginal synthetic mesh implants. We also describe the challenges, considerations, and lessons learnt during the suspension that we are now applying in the current COVID-19 pandemic which has led to activities in many RCTs across the world undergoing a temporary suspension.
There were three key phases within the temporary suspension: the decision to suspend, implementation of the suspension, and restarting. Each of these phases presented individual challenges which are discussed within this paper, along with the lessons learnt. There were obvious challenges around recruitment, delivery of the intervention, and follow-up. Additional challenges included communication between stakeholders, evolving risk assessment, updates to trial protocol and associated paperwork, maintaining site engagement, data-analysis, and workload within the trial team and Sponsor organisation.
Based on our experience of managing a temporary suspension, we developed an action plan and guidance (see Additional File 1) for managing a significant trial event, such as a temporary suspension. We have used this document to help us manage the suspension of activities within our portfolio of trials during the current COVID-19 pandemic.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Betacoronavirus - pathogenicity
/ Coronavirus Infections - diagnosis
/ Coronavirus Infections - epidemiology
/ Coronavirus Infections - transmission
/ Coronavirus Infections - virology
/ COVID-19
/ Early Termination of Clinical Trials
/ Humans
/ Medicine
/ Pneumonia, Viral - diagnosis
/ Pneumonia, Viral - epidemiology
/ Pneumonia, Viral - transmission
/ Randomized Controlled Trials as Topic - methods
/ RCT
/ Statistics for Life Sciences
/ Surgeons
/ Surgery
/ Suspend
/ Vagina
